Teva’s MS pill misses the mark in PhIII trial
admin 9th May 2017 Uncategorised 0Teva Pharmaceutical Industries and partner Active Biotech say a late-stage trial of laquinimod has missed its primary endpoint, with the drug failing to halt the progression of multiple sclerosis in patients with relapsing remitting forms of the disease (RRMS).
More: Teva’s MS pill misses the mark in PhIII trial
Source: News